

1 Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity
2 and persistence of anti-SARS-CoV-2 S antibodies

3

4 Short title: Serological Study of CoronaVac vaccine and heterologous boosters.

5

6 Leonardo Vargas^{1,#}, Nicolás Valdivieso^{1,#}, Fabián Tempio², Valeska Simon¹, Daniela Sauma¹, Lucía
7 Valenzuela³, Caroll Beltrán³, Loriana Castillo-Delgado⁴, Ximena Contreras-Benavides⁴, Mónica L.
8 Acevedo⁵, Fernando Valiente-Echeverría⁵, Ricardo Soto-Rifo⁵, Rafael I. Gonzalez⁶, Mercedes
9 Lopez^{2*}, Fabiola Osorio^{7*}, María Rosa Bono^{1*}.

10

11 1. Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile

12 2. Laboratory of Cancer Immunoediting, Immunology Program, Institute of Biomedical Sciences,
13 Faculty of Medicine, Universidad de Chile.

14 3. Immunogastroenterology Lab., Gastroenterology Unit, Hospital Clínico Universidad de Chile,
15 Faculty of Medicine, Universidad de Chile.

16 4. Hospital Clínico Metropolitano La Florida “Dra. Eloisa Diaz I.”, Froilan Roa 6542, La Florida,
17 Región Metropolitana, Santiago, Chile.

18 5. Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical
19 Sciences, Faculty of Medicine, Universidad de Chile.

20 6. Centro de Nanotecnología Aplicada, Universidad Mayor, Santiago, Chile. Center for the
21 Development of Nanoscience and Nanotechnology, CEDENNA.

22 7. Laboratory of Immunology and Cellular Stress, Immunology Program, Institute of Biomedical
23 Sciences, Faculty of Medicine, University of Chile.

24

25 # These authors contributed equally to this work

26 * Corresponding authors

27

28

29

30

31

32

33

34

35

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79

*** Correspondence:** María Rosa Bono
Laboratory of Immunology
Faculty of Sciences
Universidad de Chile
Las Palmeras 3425
Postcode: 7800003
Santiago, Chile
Phone: +56-2-29787339
Email: mrbono@uchile.cl

Fabiola Osorio
Laboratory of Immunology and Cellular Stress
Immunology Program
Institute of Biomedical Sciences
Faculty of Medicine
Universidad de Chile
Av. Independencia 1027
Postal code: 8380453
Santiago
Chile
Phone: +56-2-29789503
Email: fabiolaosorio@med.uchile.cl

Mercedes López
Laboratory of Cancer Immunoediting
Program of Immunology
Institute of Biomedical Sciences
Faculty of Medicine
Universidad de Chile
Av. Independencia 1027
Postcode: 8380453
Santiago, Chile
Phone: +56-2-29789503
Email: melopez@uchile.cl

80 **ABSTRACT**

81

82 Background: Chile was severely affected by COVID19 outbreaks but was also one of the first
83 countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile
84 became one of the fastest countries to inoculate a high percentage of the target population and
85 implemented homologous and heterologous booster schemes in late 2021 to prevent potential
86 immunological waning. The aim of this study is to compare the immunogenicity and time course
87 of the humoral response elicited by the CoronaVac vaccine in combination with homologous
88 versus heterologous boosters.

89 Methods and Findings: We compared the immunogenicity of two doses of CoronaVac and
90 BNT162b2 vaccines and studied the effect of different booster regimes in the Chilean population.
91 Our results demonstrate that a two-dose vaccination scheme with CoronaVac induces lower
92 levels of anti-SARS-CoV-2 S antibodies than BNT162b2 in a broad age range. Furthermore,
93 antibody production declines with time in individuals vaccinated with CoronaVac and less
94 noticeably, with BNT162b2. Remarkably, analysis of booster schemes revealed that individuals
95 vaccinated with two doses of CoronaVac generate immunological memory against the SARS-CoV-
96 2 ancestral strain, which can be re-activated with homologous or heterologous (BNT162b2 and
97 ChAdOx1) boosters. Nevertheless, the magnitude of the antibody response with the
98 heterologous booster regime was considerably higher and persistent (over 100 days) than the
99 responses induced by the homologous scheme.

100 Conclusions: Two doses of CoronaVac induces antibody titers against the SARS-CoV-2 ancestral
101 strain which are lower in magnitude than those induced by the BNT162b2 vaccine. However, the
102 response induced by CoronaVac can be greatly potentiated with a heterologous booster scheme
103 with BNT162b2 or ChAdOx1 vaccines. Furthermore, the heterologous booster regimes induce a
104 durable antibody response which does not show signs of decay 3 months after the booster dose.

105

106 INTRODUCTION

107
108 Chile is one of the several countries severely threatened by the COVID-19 pandemic in 2020, but
109 that had prompt access to vaccines for a large number of individuals since early 2021. The first
110 SARS-CoV-2 vaccine authorized in Chile for emergency use by the Health Ministry (MINSAL) was
111 the Pfizer-BioNTech vaccine (BNT162b2) on December 16, 2020, and Sinovac's CoronaVac
112 vaccine on January 20, 2021 (Institute of Public Health, ISP). World Health Organization (WHO)
113 listed CoronaVac for emergency use on June 1, 2021
114 (<https://covid19.trackvaccines.org/agency/who/>), which is currently administered in 48
115 countries (<https://covid19.trackvaccines.org/vaccines/7/>). In Chile, vaccination with CoronaVac
116 began on February 1, 2021, with people over 55 years old, people with specific pathologies, and
117 essential services personnel. Progressively, the vaccination scheme extended to younger people
118 (target population over 18 years old: 15,200,840). In this first phase of vaccination, the
119 CoronaVac vaccine was predominantly used across the population. Real-world data indicated
120 that the two-dose vaccination scheme with CoronaVac in Chile showed a 65.9% vaccine
121 effectiveness, 90.3% for prevention of ICU admission, and 86.3% for prevention of COVID-19
122 related death (1). To date, more than 86,8% of the Chilean population received their complete
123 vaccination schedule with any available vaccines (DEIS/MINSAL), and about 77% of the target
124 population received CoronaVac (Minsal / Deis).

125 However, around mid-2021, immunological studies reported a decline of antibody levels in
126 vaccinated individuals. These studies predicted a reduction in antibody titers directed against
127 SARS-CoV-2 over time, highlighting the requirement of an additional immunization (2) (3). In this
128 context, a group of countries, including Israel (4), and Chile authorized a booster vaccine dose.
129 On August 11, 2021, the vaccination with booster doses began for people who had received two
130 doses of Coronavac in Chile. Interestingly, Chile implemented a heterologous booster schedule
131 for most individuals including BNT162b2 and the ChAdOx1 vaccine from AstraZeneca as the most
132 used boosters. These schemes offer an important opportunity to assess the magnitude of the
133 immunological response to homologous and heterologous boosters schedules within the same
134 population. Furthermore, this issue is relevant considering that immunological studies of

135 heterologous booster schedules using CoronaVac as the first immunization vaccine have not been
136 extensively documented.

137 This study describes the production of IgG antibodies directed against the ancestral SARS-CoV-2
138 S protein induced by the two-dose scheme of the Coronavac vaccine in a Health Service of the
139 Hospital La Florida, Santiago. Our data shows that detectable levels of specific antibodies appear
140 in most vaccinated individuals. By comparing the humoral responses to CoronaVac and
141 BNT162b2 vaccines over time, we found that the antibody production elicited by CoronaVac
142 declined six months after vaccination, whereas people vaccinated with two doses of BNT162b2
143 maintained a noticeably higher level of antibodies over time. Next, we analyzed the impact of
144 the booster doses of CoronaVac, BNT162b2, or ChAdOx1 vaccines, administered to individuals
145 vaccinated with the two-dose scheme with CoronaVac six months earlier. Our data show that the
146 three types of boosters produce a noticeable increase in anti-spike IgG antibody production
147 twenty days after the booster administration, which was more strongly noticed in individuals
148 vaccinated with the heterologous booster regime. Antibody responses measured 100 days after
149 the booster dose revealed that the heterologous regime induced higher and persistent anti-SARS-
150 CoV-2 S antibodies compared to the homologous regime.

151 In summary, our results show that the CoronaVac vaccine produces memory against the SARS-
152 CoV-2 that can be greatly potentiated with a heterologous booster strategy. Moreover, the
153 persistent antibody titers obtained using the heterologous booster strategy may allow to space
154 subsequent booster doses in the population. Furthermore, these data suggests that Chile's
155 vaccination scheme has been efficient in avoiding contagion with the Delta variant, as predicted
156 by data derived from the epidemic in Chile.

157

158

159

160 **MATERIALS AND METHODS**

161

162 **Ethics Statement**

163

164 Hospital Clínico Universidad de Chile approved the study on health worker personnel (Protocol
165 ID Number 1151/20 and Protocol ID Number 074-2020). Hospital Clínico Metropolitano La Florida
166 “Dra. Eloisa Díaz I.” was included in the ethical protocols of the University of Chile as part of the
167 COVID-19 research program of ANID grant 0752. Samples obtained from non-health worker
168 individuals were approved by Facultad de Ciencias, Universidad de Chile (Protocol ID 2123-FCS-
169 UCH and consent approval). Samples were collected from February 2021 to January 2022. All
170 patients and healthy controls were required to understand the study and sign an informed
171 consent.

172

173 **Design of study groups**

174

175 We obtained blood samples from different individuals; healthcare personnel volunteers from
176 Hospital La Florida, and adult healthy volunteers (over 18 years old). These were divided in four
177 different groups; Group 1 to study the immune response following two Coronavac doses in
178 healthcare personnel; Group 2 that was designed to compare Coronavac and BNT162b2
179 vaccination; Group 3 to analyze the homologous and heterologous booster response (6 months
180 after Coronavac vaccination); and Group 4 to study the persistence of the humoral response after
181 > 100 days following the homologous and heterologous booster.

182

183 This study is composed of four groups covering the period ranging from the beginning of the
184 vaccination program in February 2021 and months after the administration of the booster doses
185 in August 2021 (depicted as timelines in Figure 1A). Group 1 corresponds to 104 individuals
186 belonging to the clinical staff from the Hospital Clínico Metropolitano La Florida “Dra. Eloisa
187 Díaz”, which were among the first cohort to be vaccinated as a priority group CoronaVac vaccine.
188 In this group of individuals, the antibody response to the first and second dose of the CoronaVac
189 vaccine was assessed.

190 Group 2 corresponds to 158 individuals from a broad range of age vaccinated with CoronaVac
191 and BNT162b2 vaccines. A comparison of IgG production against spike SARS-CoV-2 protein
192 induced by the vaccines was performed, and antibody evolution was followed over time.

193 Group 3 corresponds to 43 individuals vaccinated with the two-dose scheme of CoronaVac that
194 received a booster dose with either CoronaVac, BNT162b2, or the ChAdOx1 vaccine. This group
195 determined the magnitude of the antibody response to the homologous and heterologous
196 booster schemes 20 days after the booster. Finally, group 4 corresponds to 78 individuals
197 vaccinated with the two-dose scheme of CoronaVac that received a booster dose with either
198 CoronaVac, BNT162b2, or the ChAdOx1 vaccine and analyzed 100 days after the booster. Fig 1B
199 describes the characteristics of the volunteers who participated in each stage of the study. In
200 total, 316 individuals participated, of which 57.4% were women, and 42.6% were men. The
201 median age of the volunteers was 38 years (Interquartile range; IQR: 30-59 years). Some
202 individuals participated in group 2 and the longitudinal booster study. Thus, the number of
203 samples is higher than the number of participants.

204

205 **Isolation of human blood samples**

206 Blood samples were obtained from healthcare personnel volunteers from Hospital La Florida, and
207 adult healthy volunteers (over 18 years old). Serum was collected after whole blood
208 centrifugation and stored at -80°C for further analysis.

209

210 **ELISA**

211

212 The ELISA was performed as detailed (5), and adapted from the group of Kramer (6). Briefly, 96-
213 well ELISA plates were coated overnight at 4°C with 50 µl per well of a 2 µg/ml solution of
214 resuspended SARS-CoV-2 Spike protein (Recombinant SARS-CoV-2 S protein S1 from the original
215 Wuhan SARS-CoV-2 virus, Biolegend 796906) on PBS. Then, the coating solution was removed,
216 and the wells were blocked for one hour at room temperature with 150 µl of 3% skim milk
217 prepared in PBS-0.1% Tween-20 (TPBS). After this period, 100 µl per well of serial dilutions (from
218 1/200 to 1/1,600) of the sera prepared in 1% skim milk in 0.1% TPBS was added and incubated
219 for 2 hours at room temperature. The plates were washed three times, added 100 µl per well of

220 HRP-conjugated anti-human IgG (HRP Donkey anti-human IgG Clone: Poly24109, Biolegend), and
221 incubated for 1 hour at room temperature. The plates were washed three times, after which 50
222 μ l of TMB substrate solution (BD Biosciences) was added per well to reveal the reaction, which
223 was stopped by adding 50 μ l per well of 1M orthophosphoric acid. Optical density at 450 nm was
224 measured on a Molecular Devices Emax ELISA plate reader. We tested the specificity of our ELISA
225 assay by analyzing serum samples from unvaccinated COVID19 patients at the time where Delta
226 variant was dominant in our country. Our data confirmed that the ELISA test we performed with
227 the S protein of the original coronavirus recognizes all the variants that have entered Chile at that
228 time, including the Delta variant.

229

230 **Neutralization assay**

231

232 **HIV-1-based SARS-CoV-2 pseudotype production:** Pseudotyped viral particles were produced by
233 transient transfection of HEK293T cells using polyethylenimine (PEI) and plasmids pNL4.3- Δ Env-
234 Firefly and pCMV14-3X-Flag-SARS-CoV-2 S Δ 19C (lineage A) in a 1:1 ratio as we described (7). The
235 viral particles were diluted with 50% in fetal bovine serum (Sigma-Aldrich) and stored at -80°C.
236 Viral stock was quantified with the HIV-1 Gag p24 Quantikine ELISA kit (R&D Systems).

237 Neutralizations assays were performed as we previously reported (7). Briefly, inactivated serum
238 samples were diluted in DMEM with 10% fetal bovine serum (serial dilutions from 1:4 to 1:8748)
239 and incubated with 5 ng of p24 HIV-1-based SARS-CoV-2 pseudotyped particles during 1h at 37°C,
240 and 1×10^4 HEK-ACE2 cells were added to each well. HEK293T cells incubated with the
241 pseudotyped virus were used as a negative control. Cells were lysed 48 hours later, and firefly
242 luciferase activity was measured using the Luciferase Assay Reagent (Promega) in a Glomax 96
243 Microplate luminometer (Promega). Then the percentage of neutralization for each dilution was
244 calculated as previously described. All statistical analyses were performed using GraphPad Prism
245 version 8.0.1 (7)

246

247 **Quantification and statistical analysis:**

248

249 For the ELISA assay, the background value was established at OD 0.100, and Area Under the Curve
250 (AUC) was calculated from serum dilutions. To obtain a correlation between AUC and antibody

251 titers, we used estimated values of antibody titers from 212 samples, and we established a curve
252 according to Padé's approximation (with $R^2=0.9636$). Differences between clinical groups were
253 calculated using a one-way ANOVA with Freedman or Kruskal-Wallis test followed with Dunn's
254 multiple comparisons test. Differences between the two groups were calculated using the
255 unpaired two-tailed t-test or Mann-Whitney test. Simple linear regression was performed, and
256 correlations were analyzed by calculating nonparametric Spearman's correlation. Statistical
257 analyses were performed using GraphPad Prism 9.1.0, and statistical significance was
258 represented by * $p<0.05$, ** $p<0.01$, *** $p<0.001$, and ** $p<0.0001$.

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280 RESULTS

281 **The course of the humoral response to the CoronaVac vaccine**

282
283 Fig 1A shows the course of the COVID-19 pandemic in Chile from March 2020 to December 2021
284 (MINSAL/DEIS), which illustrates three waves of COVID-19. The first wave began on April 20, 2020
285 and ended in August 2020. The second wave, mainly caused by gamma and lambda variants, was
286 more extensive, beginning on November 1, 2020, and ending in September 2021 (MINSAL/DEIS).
287 The drop in active cases began mid-June 2021 and coincided with the drop in cases throughout
288 South America (MINSAL / DEIS, our world in data). Finally, the delta variant entered the country
289 on June 24th, 2021, and became predominant as of October of this year causing the third wave.
290 However, this variant was notably less infectious in Chile than in European
291 countries. Additionally, in the last days of November, the entry of the first case of the omicron
292 variant was reported.

293 This study is composed of four groups of individuals that were analyzed across entire the
294 vaccination and booster programs in 2021, starting February 2021 and ending in January 2022
295 (depicted as timelines in Figure 1A). The number of individuals and additional details of the study
296 are found in Fig 1B.

297

298 **Serological analysis of CoronaVac before immunization, and post-first and -second dose.**

299 To evaluate the effect of the CoronaVac vaccine on antibody titers in individuals potentially
300 exposed to the SARS-CoV-2 virus, we first focused our study on clinical staff from group 1, who
301 treated COVID-19 patients in the first wave of the disease in Chile. We analyzed the serum of
302 these individuals by ELISA to detect IgG antibodies directed against the Spike (S) protein of the
303 SARS-CoV-2 virus. This test was developed with samples from hospitalized COVID-19 patients as
304 positive controls (13 samples) and pre-pandemic or negative samples (54 samples) for negative
305 controls (5) and developed as reported (6). Sera were diluted serially from 1/200 to 1/1,600, and
306 the area under the curve (AUC) was determined. These values were equivalent to the antibody
307 titer (see Methods). We established the negative limit of the test ($AUC = 70 \pm 51$) from the

308 analysis of 54 samples from people who had no history of COVID-19. We considered AUC values
309 between 120 and 300 as a weak response in the ELISA test. In contrast, an AUC of around 300
310 corresponds approximately to an antibody titer of 1/1,000. To analyze the SARS-CoV-2 antibody
311 response course in this group, we analyzed the antibody response in three-time points. The first
312 serum sample was obtained 1-3 days before the first dose of the vaccine (referred to as
313 'Preimmune', Fig 2); the second sample was obtained 1-3 days before the second immunization
314 (referred to as 'First dose + 30d', Fig 2), and the third sample was collected one month after the
315 second dose (referred to as 'Second dose +30d', Fig 2). Regarding previous SARS-CoV-2 infection,
316 the individuals who participated in this study were laboratory staff, and primary clinical
317 caregivers in contact with COVID-19 patients. Many individuals in this group reported not
318 knowing whether they had been exposed to SARS-CoV-2 since they could have experienced the
319 asymptomatic disease.

320 Of a total of 104 people tested, 18 had high antibody titers ($AUC > 300$) before being vaccinated,
321 suggesting that these individuals were infected with SARS-CoV-2 in the first pandemic wave (Fig.
322 2A, empty circles). Of these 18 individuals, only two did not improve antibody titers with
323 vaccination (Fig. 2B orange lines). For the remaining 16 individuals (orange lines), the first dose
324 of the vaccine led to an increase in anti-S IgG production. Interestingly, there were no statistical
325 differences when comparing the level of antibodies induced by the first and the second dose of
326 the vaccine (Fig. 2B, orange circles).

327 For individuals who initially had an $AUC > 120$ (weak positive reaction, Fig 2B green circles), the
328 first dose showed an increase in the level of anti-S IgG. Although significant, there was a mild
329 difference between the first and the second doses. Interestingly, the group who initially had an
330 $AUC < 120$ (negative reaction, Fig 2B blue circles) showed remarkable differences between the
331 first and the second dose of the vaccine. Of the total 104 people, only one person remained
332 unresponsive to the two doses of the vaccine. As such, we conclude that the two-dose
333 vaccination scheme with CoronaVac induces a good antibody response against SARS-CoV2, which
334 is particularly noticed in individuals who have not been previously exposed to the virus.

335 Next, the amount of neutralizing antibodies from 34 samples obtained one month after the
336 second dose was determined. The results show a significant positive correlation between the
337 AUC values and the IC-50 of neutralizing antibodies (Fig. 2C). These results demonstrate that the
338 CoronaVac vaccine induces the production of neutralizing antibodies. Furthermore, this data
339 suggests that high titers of total antibodies should represent a greater probability of having
340 neutralizing antibodies against the virus.

341 **Comparison of the humoral immune responses produced by the CoronaVac and BNT162b2** 342 **vaccines**

343 The first reports of CoronaVac vaccine immunogenicity were performed in older adults (over 55
344 years old) (8) since these individuals were among the priority groups for vaccination. In May 2021,
345 individuals under 55 years old began to be vaccinated with BNT162b2 or CoronaVac depending
346 on the availability of the vaccine in Chile. This allowed us to analyze the antibody response 30 to
347 45 days after the second dose to compare the humoral response elicited by both vaccines. We
348 studied 44 and 20 individuals vaccinated with CoronaVac and BNT162b2 (Pfizer-BioNTech)
349 vaccine, respectively (group 2). Figure 3A shows a comparison of the data from both vaccines in
350 individuals ranging from 18-87 years old (IQR: 27-61 years). We observed that the BNT162b2
351 vaccine induces significantly higher antibody production than the CoronaVac vaccine (2060 ± 361
352 for BNT162b2 and 1041 ± 520 for CoronaVac). Given that people vaccinated with CoronaVac were
353 mainly older than 55 years in Chile and those vaccinated with BNT162b2 were people between
354 18 and 54 years old, we compared and plotted antibody production according to the age of the
355 individuals and the type of vaccine they received. Figure 3B shows a significant negative
356 correlation ($p = 0.032$, black circles) for antibody production with increasing age for the
357 CoronaVac vaccine. In contrast, a similar (but not statistically significant, green circles) trend is
358 shown for the BNT162b2 vaccine. These results show that the BNT162b2 vaccine induces twice
359 the amount of IgG against SARS-CoV-2 S protein compared to CoronaVac, independent of the age
360 of the individuals.

361 362 **Overtime evolution of the humoral response to CoronaVac and BNT162b2 vaccines** 363

364 So far, we have demonstrated the presence of neutralizing antibodies in a significant number of
365 individuals immunized with CoronaVac and demonstrated a positive correlation between the
366 amount of IgG against SARS-CoV-2 S antibodies and the production of neutralizing antibodies
367 (Fig. 2C). Moreover, we showed that the BNT162b2 vaccine produces higher levels of antibodies
368 in vaccinated people than those elicited by the CoronaVac vaccine (Fig. 3A). Therefore, we sought
369 to determine how antibody levels vary with these two vaccines over time. For this purpose, we
370 analyzed samples taken 15 to 200 days after the second dose of CoronaVac or BNT162b2
371 vaccines. One hundred and fifty-nine samples from individuals vaccinated with CoronaVac and
372 53 samples from individuals vaccinated with BNT162b2 were analyzed. Fig. 3D shows a significant
373 negative correlation for each of these vaccines (CoronaVac $p < 0.0001$; BNT162b2 $p = 0.0111$).
374 The curve slope allows us to infer that around 200 days after the second dose of the CoronaVac
375 vaccine, most individuals vaccinated will present low antibody titers against the SARS-CoV-2 S
376 protein. In contrast, in individuals vaccinated with the BNT162b2 vaccine, antibodies slightly
377 decrease in most individuals, agreeing with data from the literature (2).

378 We then disaggregated the data to visualize the results (Fig. 3C). Comparing the data obtained
379 13 to 45 days or beyond 80 days after the second dose from both vaccines, we observed a
380 significant loss of antibodies beyond 80 days after the second dose of the CoronaVac vaccine
381 ($1,057 \pm 519$ vs. 378 ± 318) compared to the BNT162b2 vaccine ($2,060 \pm 361$ vs. $1,861 \pm 351$). These
382 data suggest that the BNT162b2 vaccine is more efficient in inducing and maintaining the
383 production of antibodies against the SARS-CoV-2 virus S protein.

384 385 **Analysis of the antibody response of individuals receiving homologous or heterologous booster** 386 **dose schemes**

387
388 A total of 44 individuals who were vaccinated with two doses of CoronaVac received, around 180
389 days after the second dose, a booster dose with the ChAdOx1 vaccine (19 individuals), BNT162b2
390 vaccine (19 individuals), or CoronaVac vaccine (5 individuals) (timeline scheme depicted in Fig.
391 4A). Data illustrated in Fig. 4B show that regardless of the type of vaccine used for the booster
392 dose, all individuals significantly enhanced IgG production against the Sars-CoV-2 S Protein.
393 Values range from 268 ± 218 before the boost to $2,245 \pm 581$ considering any booster, meaning an
394 8,37-fold change average. However, when we separated the data based on the type of booster

395 vaccine, we observed that the CoronaVac booster vaccine-induced antibody production, which
396 was noticeable but milder (fold induction: 9.8x) than the antibody production induced by the
397 ChAdOx1 vaccine booster (fold induction: 12.4x) or the BNT162b2 vaccine booster (fold
398 induction: 11.2x). These results demonstrate that the CoronaVac vaccine combined with a
399 booster from CoronaVac or any other vaccine enables memory immune response to be activated,
400 in agreement with recent data (9). These authors showed that a booster with CoronaVac vaccine
401 eight months after the second dose increased neutralizing antibodies against the original virus
402 SARS-CoV-2. However, it is noteworthy to mention that the antibody response induced by the
403 third dose of the CoronaVac vaccine is lower than the two other boosters.

404 To obtain insights on the extension of the antibody response induced by the homologous and
405 heterologous booster regimes, we measured anti-SARS-CoV-2 S antibodies in 78 individuals 100
406 days after the booster dose (Median 128 days; IQR: 119-135 days) (Fig. 4C). This analysis revealed
407 that the homologous booster with CoronaVac showed a trend towards a decline in antibody
408 production, which did not reach statistical significance (Fig. 4C). However, the antibody response
409 elicited by heterologous boosters with BNT162b2 and ChAdOx1 vaccines remained higher than
410 the homologous scheme and did not show noticeable signs of immunological waning during the
411 period. Overall, our results suggest that a heterologous booster scheme using CoronaVac as the
412 basal vaccine with a booster from ChAdOx1 (AstraZeneca) vaccine or BNT162b2 (Pfizer) vaccine,
413 re-activate immune memory and elicits a potent and persistent immune response at least over a
414 3-month period.

415

416

417

418

419

420

421

422

423

424

425 **DISCUSSION**

426 This work reports the dynamics of anti-S IgG after SARS-CoV2 vaccination with CoronaVac, a
427 vaccine used globally (10), a comparison with an mRNA vaccine over time, and an assessment of
428 homologous and heterologous booster schemes in Chile using CoronaVac as the basal vaccine.
429 The groups analyzed in this study span the entire vaccination program in Chile, from the
430 beginning of the vaccination schedule with priority groups, to the implementation of booster
431 schemes in late 2021.

432

433 Our data indicate that in individuals not exposed to SARS-CoV-2, a two-dose vaccination scheme
434 with CoronaVac induces a noticeable antibody response against SARS-CoV-2, in agreement with
435 additional reports (9). Furthermore, there is a positive correlation between the production of
436 neutralizing antibodies and those detected by ELISA (AUC). When comparing CoronaVac and
437 BNT162b2 vaccines, we found that the BNT162b2 vaccine is more efficient in inducing and
438 maintaining the production of antibodies against the SARS-CoV-2 virus S protein independent of
439 the age of the individuals. Moreover, we evaluated three different booster schemes in people
440 previously vaccinated with CoronaVac. We found that a homologous booster with CoronaVac or
441 heterologous boosters with ChAdOx1 (AstraZeneca) vaccine or BNT162b2 (Pfizer) vaccine can
442 elicit a humoral immune response against the ancestral strain of the virus. However, our data
443 strongly indicates that heterologous booster regimes greatly potentiate antibody responses
444 compared to a homologous regime. As such, our findings may have relevant implications for the
445 large number of countries currently administering a two-dose scheme of CoronaVac.

446

447 Concerning the booster schemes, administration of a homologous booster scheme of CoronaVac
448 has been demonstrated to be immunogenic and safe in a double-blind, randomized, placebo-
449 controlled phase-2 clinical trial (9). In this context, the homologous and heterologous booster
450 schemes analyzed in this work re-activated anti-S IgG production in individuals previously
451 vaccinated with the two-dose scheme of CoronaVac. Analysis over a more extended period of
452 time (more than 100 days) revealed that heterologous booster schemes are capable of inducing

453 an elevated and long-lasting antibody response compared to two-doses plus a booster of
454 CoronaVac. Thus, these data suggest that the use of heterologous instead of homologous booster
455 regimes may allow to space the subsequent booster doses to achieve long-lasting humoral
456 response and protection against COVID19. These findings also provide evidence that will allow to
457 prioritize the subsequent booster doses in individuals that have lost optimal anti-SARS-CoV-2
458 antibodies, such as those with the homologous regime.

459 It remains to be observed if these heterologous regimes potentiate an immune response that
460 could provide protection (or partial protection) against novel variants. In this context, many
461 questions remain to be addressed. For instance, although we provide data of over 3 months after
462 the booster, it is unclear how long the protection mediated these booster schemes will last or if
463 these strategies will efficiently protect against novel variants such as delta and the recently
464 described omicron (11). In this regard, a very recent study of a heterologous booster scheme
465 based on CoronaVac + BNT162b2 in the Dominican Republic showed a reduced antibody
466 response towards the Omicron variant (12). One distinction between that study and the data
467 presented here relates to the timing between the second dose and the booster, which in Chile
468 was implemented after a six-month interval, whereas in the Dominican Republic study, the
469 heterologous booster scheme was implemented after four weeks (12). As such, the immune
470 response elicited under two different time schemes may differ in terms of the magnitude of
471 antibody production. Thus, future work combined with clinical studies are required to determine
472 the optimal time between vaccine and booster administration. Along these lines, the study of
473 Zeng et al demonstrates that extending the interval of eight months between the second and the
474 homologous booster dose with CoronaVac greatly increases antibody production (9).
475 Interestingly, our study also reports potent responses with the heterologous booster scheme
476 with the ChAdOx1 vaccine, requiring further assessment. In addition, our work is also in line with
477 a very recent report showing that heterologous booster regimes are superior to homologous
478 booster schemes based on the CoronaVac vaccine in a Brazil study (13).

479 One limitation of our study is that we assessed antibody production against the spike protein of
480 SARS-CoV2 but a relevant response mediating long-lasting immunity could also be carried out by
481 T cells, which are not analyzed in this work. However, a recent study with 15 volunteers with no

482 suspected history of COVID-19, vaccinated with two doses of CoronaVac showed humoral and
483 cellular immune response 28d after the second dose (14).

484 As such, it is possible that a heterologous booster scheme based on CoronaVac as the basal
485 vaccine could lead to potent immunity, based on the diversity of viral antigens provided by an
486 inactivated virus formulation, followed by a booster with mRNA or adenoviral vector vaccines,
487 which trigger a superior degree of immunogenicity. The long-term immunological effects related
488 to protection against SARS-CoV-2' variants of concerns and variants of interests induced by
489 heterologous booster strategies should be determined with high priority in order to shed light on
490 the future management of the pandemic across the globe.

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521 **Acknowledgments**

522

523 We thank all the volunteers who collaborated in this work, particularly the Clinical Laboratory of
524 the La Florida Hospital staff, the staff who work at the Juan Gomez Millas Campus, and many
525 other volunteer's collaborating with the study. Thanks to the 2021 generation Biotechnology
526 Engineering students for their interest in participating in a real-world experiment.

527

528 **Financial Disclosure statements:**

529 This work was supported by a grant from the COVID-19 research program of the National Agency
530 for Research and Development (ANID), grant No 0752 (MRB, FO, ML). MRB and DS are supported
531 by ANID/BASAL/FB210008, and FONDECYT grants No 1191438 (MRB) and 1180385 (DS). FO is
532 supported by an International Research Scholar grant from HHMI (HHMI#55008744), a
533 FONDECYT grant No. 1200793, and ECOS-CONICYT grant (ECOS180052). CB is supported by a
534 FONDECYT grant No 1181699. RSR is supported by a FONDECYT grant No 1190156. FVE is
535 supported by a FONDECYT grant No 1211547. RG is supported by FONDECYT grants No 11180557
536 and CEDENNA AFB180001. The sponsors of the study had no role in study design, data collection,
537 data analysis, data interpretation, or writing of the report.

538

539 **Competing Interests:** The authors declare that they have no competing financial interests.

540

541 **Author contributions**

542 Conceptualization: MRB/FO/ML/LC; Data Curation: MRB, LV, VS; Formal Analysis: LV/NV/MLA;
543 Funding Acquisition: MRB/FO/ML/RSR/FV; Investigation: MRB/FO/ML; Methodology:
544 LV/NV/MLA; Project Administration: MRB/LV/VS; Resources: MRB/FO/ML/LC/CB/LV;
545 Supervision: MRB; Validation: LV/NV/MRB/FO/RSR; Visualization: NV/DS/RG; Writing-Original
546 Draft Preparation: MRB/FO; Writing- Review & Editing: MRB/FO/ML/DS.

547

548

549 **REFERENCES**

550

- 551 1. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of
552 an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med*. 2021;385(10):875-84.
- 553 2. Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A, et al. Dynamics of
554 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.
555 *Lancet Reg Health Eur*. 2021;10:100208.
- 556 3. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
557 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
558 infection. *Nat Med*. 2021;27(7):1205-11.
- 559 4. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al.
560 Protection against Covid-19 by BNT162b2 Booster across Age Groups. *N Engl J Med*.
561 2021;385(26):2421-30.
- 562 5. Garcia-Gonzalez P, Tempio F, Fuentes C, Merino C, Vargas L, Simon V, et al. Dysregulated
563 Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen
564 Requirements. *Front Immunol*. 2021;12:769059.
- 565 6. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al.
566 A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020;26(7):1033-
567 6.
- 568 7. Beltran-Pavez C, Riquelme-Barrios S, Oyarzun-Arrau A, Gaete-Argel A, Gonzalez-
569 Stegmaier R, Cereceda-Solis K, et al. Insights into neutralizing antibody responses in individuals
570 exposed to SARS-CoV-2 in Chile. *Sci Adv*. 2021;7(7).
- 571 8. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity
572 of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a
573 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*.
574 2021;21(6):803-12.
- 575 9. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third
576 dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim
577 results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical
578 trials. *Lancet Infect Dis*. 2021.
- 579 10. Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning.
580 *Nature*. 2021;598(7881):398-9.
- 581 11. Pulliam JRCvS, C.; Govender, N.; von Gottberg, A.; Cohen, C.; Groome, M.J.; Dushoff, J.;
582 Mlisana, K.; Moultrie, H. Increased risk of SARS-CoV-2 reinfection associated with emergence of
583 the Omicron variant in South Africa. *medRxiv*. 2021.
- 584 12. Perez-Then EL, C.; Silva Monteiro, V.; Miric, M.; Brache, V.; Cochon, L.; Vogels, C.B.F.; De
585 la Cruz, E.; Aidelis, J.; De los Santos, M.; Leon, P.; Breban, M.I.; Billig, K.; Yildirim, I.; Pearson, C.;
586 Downing, R.; Gagnon, E.; Muyombwe, A.; Razeq, J.; Campbell, M.; Ko, A.; Omer, S.B.; Grubaugh,
587 N.D.; Vermund, S.H.; Iwasaki, A. Immunogenicity of heterologous BNT162bb2 booster in fully
588 vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the
589 Dominican Republic experience. 2021.
- 590 13. Costa Clemens SAaW, Lily Yin and Clemens, Ralf and Almeida Mendes, Ana Verena and
591 Ramos Souza, Alessandra and Silveira, Mariana V. and Nascimento Farias da Guarda, Suzete and
592 Miyamoto de Nobrega, Maristela and de Moraes Pinto, Maria Isabel and Gonzalez, Isabela G. S.

593 and Salvador, Natalia and Franco, Marilia Miranda and de Avila Mendonça, Renata Navis and
594 Queiroz Oliveira, Isabelle Silva and de Freitas Souza, Bruno Solano and Fraga, Mayara and Aley,
595 Parvinder K. and Bibi, Sagida and Cantrell, Liberty and Lambe, Teresa and Voysey, Merryn and
596 Pollard, Andrew J. and Team, RHH-001 Study, Available at SSRN:
597 <https://ssrn.com/abstract=3989848> or <http://dx.doi.org/10.2139/ssrn.3989848>. Randomized
598 Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster
599 Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine. 2021.
600 14. Escobar AR-L, F.; Acevedo, M.L.; Alonso-Palomares, L.; Valiente Echeverria, F.; Soto-Rifo,
601 R.; Portillo, H.; Gatica, J.; Flores, I.; Nova-Lamperti, E.; Barrera-Avalos, C.; Bono, M.R.; Vargas, L.;
602 Simon, V.; Leiva-Salcedo, E.; Vial, C.; Hormazabal, J.; Cortes, L.J.; Valdes, D.; Sandino, A.M.;
603 Imarai, M.; Acuña-Castillo, C. Evaluation of the Immune Response Induced by CoronaVac 28-
604 Day Schedule Vaccination in a Healthy Population Group
605 Front Immunol. 2021;12.

606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636

637 **Figure Legends**

638

639 **Figure 1: Course of the COVID-19 pandemic in Chile and details of the participants of this study.**

640 A) Chile had three waves of COVID-19. The first begun on April 2020, and ended in August 2020.
641 The second wave was mainly caused by gamma and lambda variants and it was more extensive,
642 beginning in November 1, 2020, and ending in September 2021 (Data extracted from
643 MINSAL/DEIS). Finally, the delta variant entered the country on June 24th, 2021, and became
644 predominant as of October 2021. The black curve depicts the daily cases of COVID-19, while the
645 red curve represents deceased people due to COVID-19 during the period.

646 B) Characteristics of the volunteers participating in different stages of this study. Group 1 was
647 was composed of health care personal from HLF and was designed to test pre-immunization with
648 CoronaVac, one month after the first and one month after the second dose. Group 2 contains
649 samples from healthy donors recruited to compare the antibody response to CoronaVac and
650 BNT162b2 one month after the second dose. In group 3, we studied the effect of a homologous
651 or heterologous booster scheme in the antibody response of people vaccinated six months
652 before with two-doses of CoronaVac. Samples were collected 20 days after the booster. In group
653 4, the antibody response was determined 100 days after the booster date in individuals who
654 received two-doses of the CoronaVac vaccine originally. Values are the mean and interquartile
655 range (IQR).

656

657 **Figure 2: Serological analysis of CoronaVac before immunization, and post-first and -second**

658 **dose. Correlation with neutralization antibodies.** Health Care services volunteers received a
659 complete CoronaVac vaccination scheme. Serum samples were collected as indicated:
660 PreImmune, prior to the first dose, first dose + 30d, 30 days after the first dose, second dose +
661 30d, 30 days after the second dose. A) and B) Serum reactivity to SARS-Cov-2 S protein was
662 expressed as 21imp under the curve (AUC) obtained from four serial dilutions from 1/200 to
663 1/1,600 for each 21imple. A) Data from 104 volunteers are shown before vaccination, 30 days
664 after the first, and 30 days after the second dose. The gray circles show the values of people who
665 contracted the disease before vaccination. Black circles are from the other 86 samples being
666 negative or weakly positive. Negative controls were obtained from 54 pre-pandemic or COVID-
667 19 negative samples and 13 positive controls from COVID-positive patient samples. Significance
668 was assessed by nonparametric Friedman test with Dunn's multiple comparisons test, and
669 comparison between positive control and second dose +30d was determined with Mann-
670 Whitney test. B) Data shown in A) were disaggregated into three groups 21imple21n AUC values
671 before vaccination: 18 Individuals with an AUC> 300 (positive) are shown in orange, 26 with an
672 AUC> 120 (weakly positive) in 21impl, and 60 individuals negative for SARS-CoV-2 prior to
673 vaccination in blue. In each case, significance was assessed by the nonparametric Friedman test
674 with Dunn's multiple comparisons test. C Neutralization assay using CELLS DEL ENSAYO. C)
675 SerumC neutralization capacity in vaccinated participants 30 days after the second dose was
676 correlated with correspondent AUC. Significance was assessed with Spearman's 21imp
677 correlation, and simple linear regression determined the R2 value. Each dot represents a single
678 serum 21imple. ****p<.0001 ***p<.001 *p<.05.

679

680 **Figure 3 Comparison of antibody response to CoronaVac and BNT162b2 vaccines over time and**
681 **range of age.** Healthy participants received a complete vaccination scheme, and serum samples
682 were collected after the second dose at the indicated time. A) and B) Comparisons between the
683 antibody titers of samples obtained between 30 to 45 days after the second dose. Forty-four
684 individuals vaccinated with CoronaVac and 20 with BNT162b2 (green) A) Direct comparison
685 between the antibody titers against SARS-CoV-2 S protein of CoronaVac (black) or BNT162b2
686 (green) vaccine. A nonparametric Mann-Whitney test assessed significance. B) Correlation
687 between age and antibody titers of individuals vaccinated with CoronaVac and BNT162b from
688 the serum of first 45 days. Significance was assessed by Spearman correlation with significant
689 value for CoronaVac, and simple linear regression determined R2 value. Each dot represents a
690 single serum sample. C) and D) Antibody titers from 138 samples collected more than 80 days
691 after the second dose. C) Samples from 13 to 45 days were compared to samples from more than
692 80 days from CoronaVac (black) or BNT162b2 (green) vaccine scheme; nonparametric Kruskal-
693 Wallis assessed significance with Dunn's multiple comparisons test. Each dot represents a single
694 serum sample. D) Correlation between age and antibody titers of individuals vaccinated with
695 CoronaVac and BNT162b along time. Significance was assessed by Spearman correlation with
696 significant value for both vaccines and simple linear regression determined R2 value. Each dot
697 represents a serum sample. ****p<.0001 ***p<.001 *p<.05.


698
699 **Figure 4 Antibody titers of homologous and heterologous boosters of individuals previously**
700 **vaccinated with two doses of CoronaVac.** Participants received a complete CoronaVac
701 vaccination scheme and booster after 6 to 8 months with BNT162b2, ChAdOx1, or CoronaVac
702 vaccine. Serum samples were collected as indicated: Before Boost and 20 days after Boost to
703 evaluate the change of antibody titer. A) Schema of participant's immunizations. B) Antibody titer
704 comparison before and 15 days post booster immunization from BNT162b2 (19 individuals)
705 ChAdOx1 (19 individuals), and CoronaVac (5 individuals). C) Antibody titer comparison 100 days
706 post booster immunization (Median 128 days; IQR: 119-135 days) from BNT162b2 (27
707 individuals) ChAdOx1 (41 individuals), and CoronaVac (10 individuals). Significance was assessed
708 by paired parametric t-test ('BNT162b2' and 'CoronaVac') or paired nonparametric Willcoxon test
709 ('All Boosters' and 'ChAdOx1'). Each dot represents a serum sample. ****p<.0001 **p<.01.

710

711

712

Figure 1



B Volunteers participating in this study

	Group 1	Group 2	Group 3	Group 4
Age	35 (30-42)	39 (27-61)	61 (40-67)	60 (39-69)
Sex				
Male	16 (15.38%)	65 (41.14%)	15 (34.88%)	28 (35.90%)
Female	88 (84.62%)	93 (58.86%)	28 (65.12%)	50 (64.10%)
Total	104	158	43	78

Figure 2




Figure 3




Figure 4

